Enzolytics, Inc. (OTC PINK: ENZC) stock closed 20.35% up from Tuesday’s closing, reaching $0.343 in Wednesday’s session. In comparison to the past 30-day volume of 40,601,646, 84,232,468 shares were traded yesterday.
On February 1, 2021, The Company’s primary anti-HIV monoclonal antibody is aimed at one retained site of the HIV virus, which comprises 98 percent (either directly or by conservative amino acid substitutions) of all 87,336 HIV isolates that have now been compiled (analyzed) by the Firm using Ai Technology (AI).
In the Institute for Preclinical Studies on Texas A&M University’s campus, additional conserved target sites have now been identified against which fully human anti-HIV monoclonal antibodies will be produced in a lab. It is recognized that producing multiple monoclonal antibodies against various conserved sites is crucial to effective treatment. Consequently, a cocktail of antibodies targeting conserved and immutable sites can be administered.
The Company’s Genetics and Molecular Biology data science team is now screening; through computer analysis/artificial intelligence (AI), all 275,000 known CoronaVirus isolates for conserved sites would be expected to be immutable. This information will lead to the production of anti-SARS-CoV-2 monoclonal antibodies.
Scientists are working to provide insights into the prevention and treatment of diseases that have been unknown previously. Investing in Biotech during this period may mean significant returns for investors if approval can be obtained from authorities.